secwatch.observer — SEC 8-K summary
======================================

Issuer:     DAVITA INC. (DVA)
CIK:        0000927066
Form:       8-K
Filed at:   2022-05-26T23:59:59+00:00
Accession:  0000927066-22-000110
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

DaVita and Medtronic form joint venture to create independent kidney-care device company
--------------------------------------------------------------------------------

- Equal equity stakes; Medtronic contributes Renal Care Solutions; DaVita pays $75M cash and $25M other assets.
- Each contributes $200M cash to launch NewCo; up to $300M milestone payments possible through 2028.
- Expected close in 2023, subject to HSR and other regulatory approvals.
- DaVita expects quarterly charges ~$20M after close, decreasing to zero in 2-3 years as NewCo reaches breakeven.
- Independent management and six-person board with two directors from each parent plus two independents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/927066/000092706622000110/0000927066-22-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/927066/000092706622000110/dva-20220525.htm
  HTML page:      https://secwatch.observer/filing/0000927066-22-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer